The DOI matches its Crossref record.
Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
Abstract
The gp100 melanoma-associated tumor Ag was selected as a model system to study the diversity of human antitumor cytotoxic T cell responses. First, peptides corresponding to dominant gp100 HLA-A2.1-restricted CTL epitopes were tested using lymphocytes from normal volunteers and an in vitro priming protocol that uses peptide-pulsed dendritic cells as APCs and IL-7 and IL-10 as immune-enhancing cytokines. High CTL activity toward both peptide-pulsed target cells and gp100+ melanoma cells was obtained with four out of five peptides tested. Second, HLA-A2.1-binding peptides from gp100 that do not appear to represent CTL epitopes in melanoma patients were also tested for their capacity to induce CTL using the in vitro priming protocol. Three of six peptides tested induced CTL in lymphocytes from normal volunteers. One of these peptides was also immunogenic for lymphocytes derived from a melanoma patient in remission. Because these three CTL epitopes were not recognized in the natural immune response in melanoma patients but do appear as immunogens when peptides are used to induce the T cell response, they may be considered as typical "subdominant" epitopes. The results are discussed in the context of the usefulness of this approach to detail the immunologic potential of a given tumor-associated Ag and its relevance for the design of effective immune-based therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Self-citationA listing of human tumor antigens recognized by T cells
Renkvist, N., Castelli, C., Robbins, P. F., & Parmiani, G. (2001) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620000169 · Cited by 694
Dendritic Cells in Cancer Immunotherapy
Fong, L., & Engleman, E. G. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.245 · Cited by 680
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Southwood, S., Sidney, J., Kondo, A., del Guercio, M.-F., Appella, E., Hoffman, S., Kubo, R. T., Chesnut, R. W., Grey, H. M., & Sette, A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.7.3363 · Cited by 665
Self-citationNine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
Sette, A., & Sidney, J. (1999) · Immunogenetics · doi:10.1007/s002510050594 · Cited by 635
Self-citation
Metadata
- Authors
- Tsai, V, Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., & Celis, E.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-02
- Volume
- 158
- Issue
- 4
- Pages
- 1796-1802
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1555916481
- Cited by
- 175
- References
- 0
- FWCI
- 8.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. https://app.cochat.ai/papers/10.4049/jimmunol.158.4.1796
- The paper
- Tsai, V, Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., & Celis, E. (1997). Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.158.4.1796
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.